Cellular and Molecular Mechanisms of FUS-related ALS/FTD

FUS相关ALS/FTD的细胞和分子机制

基本信息

  • 批准号:
    10370356
  • 负责人:
  • 金额:
    $ 38.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-04-15 至 2024-02-29
  • 项目状态:
    已结题

项目摘要

ALS is a late-onset progressive neurodegenerative disease caused by degeneration of motor neurons, and a disease hallmark is the accumulation of ubiquitin-positive aggregates in neuronal cytoplasm. FUS was identified as genes mutated in both familial and sporadic forms of ALS. In fact, a subset of patients with frontotemporal dementia (FTD) show FUS pathology. FUS, similar to TDP-43, is an RNA binding protein implicated in multiple aspects of RNA metabolism, including splicing, trafficking, and translation. The precise mechanisms of mutated FUS in ALS pathogenesis are not known. To understand the molecular mechanisms of FUS-mediated neurodegeneration, we developed cellular (mammalian primary neuronal and patient-derived iPSC motor neuron) and Drosophila models that recapitulate key features of human disease including cytoplasmic mislocalization, neuromuscular junction defects, locomotor dysfunctions, reduced life span, perturbed stress granule dynamics and toxicity. We discovered muscleblind and drosha as unexpected and novel modifiers of mutant FUS toxicity. MBNL proteins, highly conserved from lower organisms to vertebrates, have been implicated in many neurodegenerative disorders, such as myotonic dystrophy and CAG repeat diseases. The long-term goal is to identify modifiers of FUS toxicity and understand their molecular mechanisms using mammalian cell culture and Drosophila models. The objective of our current application is to determine how muscleblind and drosha modulate FUS-mediated toxicity in Drosophila and FUS iPSC motor neurons. We hypothesize that muscleblind and drosha regulate RNA splicing, SG dynamics and miRNA biogenesis that is perturbed by pathogenic mutations in FUS. We will examine the impact of muscleblind and drosha on cellular and molecular pathologies in FUS-associated neurodegeneration. We expect to dissect the molecular pathways that could be exploited for developing therapeutic interventions for ALS/FTD patients.
ALS是一种迟发性进行性神经退行性疾病, 神经元,疾病的标志是泛素阳性聚集体的积累, 神经细胞质FUS被鉴定为在家族性和散发性形式的FUS中突变的基因。 人症事实上,额颞叶痴呆(FTD)患者的一个子集显示FUS病理。 FUS与TDP-43相似,是一种RNA结合蛋白,涉及RNA的多个方面 代谢,包括剪接,运输和翻译。突变的确切机制 FUS在ALS发病机制中的作用尚不清楚。 为了了解FUS介导的神经变性的分子机制,我们开发了 细胞(哺乳动物原代神经元和患者来源的iPSC运动神经元)和果蝇 这些模型概括了人类疾病的关键特征,包括细胞质错误定位, 神经肌肉接头缺陷,运动功能障碍,寿命缩短,压力扰动 颗粒动力学和毒性。我们发现muscleblind和drosha是意想不到的和新奇的 突变FUS毒性的修饰剂。MBNL蛋白,从低等生物到 脊椎动物,已经涉及许多神经退行性疾病,如肌强直性疾病, 营养不良和CAG重复疾病。长期目标是确定FUS毒性的修饰剂 并利用哺乳动物细胞培养和果蝇来了解它们的分子机制 模型我们当前应用的目的是确定肌盲和drosha 调节果蝇和FUS iPSC运动神经元中FUS介导的毒性。我们假设 肌盲和drosha调节RNA剪接,SG动力学和miRNA生物合成, FUS中的致病性突变所干扰。我们将研究肌盲的影响, Drosha对FUS相关神经变性的细胞和分子病理学的研究。我们预计 来剖析分子途径, 对ALS/FTD患者进行干预。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Udai B Pandey其他文献

Udai B Pandey的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Udai B Pandey', 18)}}的其他基金

Identifying the molecular mechanisms of GEMIN5 mutations in a novel cerebellar ataxia syndrome
鉴定新型小脑共济失调综合征中 GEMIN5 突变的分子机制
  • 批准号:
    10753403
  • 财政年份:
    2023
  • 资助金额:
    $ 38.75万
  • 项目类别:
Targeting epigenetic modifiers of androgen receptor activity and toxicity in SBMA
SBMA 中雄激素受体活性和毒性的表观遗传修饰因子
  • 批准号:
    9754495
  • 财政年份:
    2019
  • 资助金额:
    $ 38.75万
  • 项目类别:
Cellular and Molecular Mechanisms of FUS-related Amyotrophic Lateral Sclerosis
FUS相关肌萎缩侧索硬化症的细胞和分子机制
  • 批准号:
    9303039
  • 财政年份:
    2017
  • 资助金额:
    $ 38.75万
  • 项目类别:
Cellular and Molecular Mechanisms of FUS-related Amyotrophic Lateral Sclerosis
FUS相关肌萎缩侧索硬化症的细胞和分子机制
  • 批准号:
    9230443
  • 财政年份:
    2014
  • 资助金额:
    $ 38.75万
  • 项目类别:
Cellular and Molecular Mechanisms of FUS-related Amyotrophic Lateral Sclerosis
FUS相关肌萎缩侧索硬化症的细胞和分子机制
  • 批准号:
    9014564
  • 财政年份:
    2014
  • 资助金额:
    $ 38.75万
  • 项目类别:
Cellular and Molecular Mechanisms of FUS-related Amyotrophic Lateral Sclerosis
FUS相关肌萎缩侧索硬化症的细胞和分子机制
  • 批准号:
    8811504
  • 财政年份:
    2014
  • 资助金额:
    $ 38.75万
  • 项目类别:
Cellular and Molecular Mechanisms of FUS-related ALS/FTD
FUS相关ALS/FTD的细胞和分子机制
  • 批准号:
    9901635
  • 财政年份:
    2013
  • 资助金额:
    $ 38.75万
  • 项目类别:
Cellular and Molecular Mechanisms of FUS-related ALS/FTD
FUS相关ALS/FTD的细胞和分子机制
  • 批准号:
    9763021
  • 财政年份:
    2013
  • 资助金额:
    $ 38.75万
  • 项目类别:
Cellular and Molecular Mechanisms of FUS-related Amyotrophic Lateral Sclerosis
FUS相关肌萎缩侧索硬化症的细胞和分子机制
  • 批准号:
    8529133
  • 财政年份:
    2013
  • 资助金额:
    $ 38.75万
  • 项目类别:
Cellular and Molecular Mechanisms of FUS-related ALS/FTD
FUS相关ALS/FTD的细胞和分子机制
  • 批准号:
    10582582
  • 财政年份:
    2013
  • 资助金额:
    $ 38.75万
  • 项目类别:

相似海外基金

Amyotrophic Lateral Sclerosis: treating the circuit behind the disease
肌萎缩侧索硬化症:治疗疾病背后的回路
  • 批准号:
    MR/Y014901/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.75万
  • 项目类别:
    Research Grant
Dysregulation of RNA processing as a driver of motor neuron dysfunction in Amyotrophic Lateral Sclerosis
RNA 加工失调是肌萎缩侧索硬化症运动神经元功能障碍的驱动因素
  • 批准号:
    MR/Y014286/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.75万
  • 项目类别:
    Research Grant
Fasciculation IN Amyotrophic Lateral Sclerosis Using MUMRI (FINALSUM)
使用 MUMRI 治疗肌萎缩侧索硬化症的肌束颤动 (FINALSUM)
  • 批准号:
    MR/Y503502/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.75万
  • 项目类别:
    Research Grant
I-Corps: Developing A Blood-Based Biomarker for the Detection and Monitoring of Amyotrophic Lateral Sclerosis
I-Corps:开发一种基于血液的生物标志物,用于检测和监测肌萎缩侧索硬化症
  • 批准号:
    2317745
  • 财政年份:
    2023
  • 资助金额:
    $ 38.75万
  • 项目类别:
    Standard Grant
Targeted immunotherapy for amyotrophic lateral sclerosis and frontotemporal dementia
肌萎缩侧索硬化症和额颞叶痴呆的靶向免疫治疗
  • 批准号:
    10759808
  • 财政年份:
    2023
  • 资助金额:
    $ 38.75万
  • 项目类别:
Resolving the Role of Neuronal STING in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
解决神经元 STING 在肌萎缩侧索硬化症和额颞叶痴呆中的作用
  • 批准号:
    10606865
  • 财政年份:
    2023
  • 资助金额:
    $ 38.75万
  • 项目类别:
Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS)
开发 CM-CS1 CAR Treg 治疗肌萎缩侧索硬化症 (ALS)
  • 批准号:
    10696512
  • 财政年份:
    2023
  • 资助金额:
    $ 38.75万
  • 项目类别:
Metrics for Brain Controlled Communication: A comprehensive review of clinical outcome assessments for communication brain computer interfaces in amyotrophic lateral sclerosis
脑控制通信指标:肌萎缩侧索硬化症通信脑机接口临床结果评估的全面综述
  • 批准号:
    10848139
  • 财政年份:
    2023
  • 资助金额:
    $ 38.75万
  • 项目类别:
The Gut Microbiota as a Contributor to Sexual Dimorphism in Amyotrophic Lateral Sclerosis
肠道微生物群是肌萎缩侧索硬化症性别二态性的一个促成因素
  • 批准号:
    488892
  • 财政年份:
    2023
  • 资助金额:
    $ 38.75万
  • 项目类别:
    Operating Grants
The biochemical stratification of amyotrophic lateral sclerosis
肌萎缩侧索硬化症的生化分层
  • 批准号:
    MR/Y001095/1
  • 财政年份:
    2023
  • 资助金额:
    $ 38.75万
  • 项目类别:
    Fellowship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了